Zibotentan

DB06629InvestigationalSmall molecule

Investigated for use/treatment in prostate cancer.

Chemical structure of Zibotentan
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in prostate cancer.Curator reviewed
Formula / weight
C19H16N6O4S · 424.44 g/mol (avg)
Code names
AZD-4054 · ZD-4054

Resolves to

Compound
UNII8054MM4902CAS186497-07-4ChEMBLCHEMBL1628688ChEBI94573
Structure
InChIKeyFJHHZXWJVIEFGJ-UHFFFAOYSA-NSMILESCOC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1
Targets
P25101EDNRA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
30Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Zibotentan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In